BeiGene Announces Completion of an Initial Public Offering of 22.2 billion RMB (3.5 billion USD) of shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange

The total number of shares issued on the Science and Technology Innovation Board is 115,055,260 common shares, each with a par value of 0.

Before deducting commissions from the underwriters and other estimated issuance expenses, the total amount of funds raised from BeiGene’s sci-tech innovation board issuance is approximately 22.

China International Capital Corporation and Goldman Sachs Gaohua Securities Co.

BeiGene has granted China International Capital Corporation a 30-day over-allotment option so that the company can over-allot no more than 17,258,000 RMB shares

BeiGene plans to invest the net proceeds from the sci-tech innovation board issuance into drug research, clinical development, construction of R&D centers and production bases in China, expansion of China's marketing team, as well as for supplementary working capital and general corporate purposes

In accordance with applicable Chinese laws and regulations, this sci-tech innovation board issuance will only be conducted within China and only for the rules and regulations promulgated by the Shanghai Stock Exchange and the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") Investors who are eligible to participate in this sci-tech innovation board issuance issue shares

The company has submitted Form S-3 to the U.

This press release does not constitute an offer or invitation to purchase the above-mentioned securities; in any country or jurisdiction, if the above-mentioned offer or invitation is made before registration or qualification certification in accordance with the local securities laws, it is an illegal act and shall not be The issuance or sale of the aforementioned securities in that country or jurisdiction

About BeiGene

BeiGene is a global biotechnology company based on science, focusing on the development of innovative and affordable medicines, aiming to improve treatment outcomes and access to medicines for patients around the world

Notes on forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 (Private Securities Litigation Reform Act of 1995), which relates to BeiGene’s current intentions, expectations or assumptions regarding this sci-tech innovation board issuance , Including its expectations for the over-allotment option and the use of the raised funds